Transcription and Batch Number

The main effect of pharmaco-therapeutic effects of drugs: a powerful inhibitor of tyrosine kinase receptor epidermal growth factor HER1/REFR; responsible for tyrosine phosphorylation of intracellular process Diphtheria Tetanus HER1/REFR expressed on the surface of both normal and cancer cells, inhibition of EGFR fosfotyrozynu stops the growth of tumor cell lines and / or lead to their death. The main pharmaco-therapeutic action: enzyme inhibitor, a number of groups of kinases, which reduces the proliferation of tumor cells in vitro; inhibits multiple intracellular kinases (c-CRAF, BRAF and mutated BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-?); many of which are involved in signal transduction of tumor cells, angiogenesis paperback apoptosis, inhibits tumor growth of human hepatocellular carcinoma and renal-cell carcinoma and several other human tumor ksenotransplantantiv deleted in mice with thymic ; on models here human hepatocellular carcinoma and renal-cell carcinoma was noted decrease angiogenesis in tumor growth and paperback of tumor cells, on the model of human hepatocellular carcinoma decreased signal cancer cells. Method of production of drugs: Table., Coated tablets, 250 mg. Pharmacotherapeutic group: L01XE - inhibitor here protein-tyrosine kinase. Contraindications to the use of drugs: hypersensitivity to the drug. Preparations of drugs: Table.-Coated 25 mg, 100 mg, 150 mg. Dosing and Administration of drug: internal, 250 mg 1 g / day, regardless of the meal. Side effects and complications in the use of drugs: diarrhea, rash, alopecia and palmar-pidoshvova erytrodyzesteziya (palmar skin pidoshvovyy-c-m), anorexia, headache, hypertension, hot flashes, diarrhea, nausea, vomiting, constipation, rash, alopecia, pruritus, erythema, dry skin, peeling skin, arthralgia, pain in extremities, fatigue, asthenia.